Key result
Apixaban yields comparable bleeding risk in high-risk versus reference TKR and THR patients.
Why the study?
Does increased apixaban exposure increase bleeding risk in patients undergoing orthopedic surgery?
Does increased apixaban exposure increase bleeding risk in patients undergoing orthopedic surgery?
Model-based analysis suggests that apixaban 2.5 mg twice daily does not require dose adjustment in orthopedic surgery patients with combined risk factors for high exposure (e.g., elderly, low body weight, renal impairment).
Answers are grounded in this paper and cite their sources.
Model predictions support standard apixaban dosing without adjustment in high-risk orthopedic patients; extends exposure-response modeling but leaves prospective validation open.
Population pharmacokinetic (PK) and exposure-response analyses of apixaban were performed using data from phase I-III studies to predict bleeding risks for patients receiving apixaban 2.5 mg b.i.d. after total knee or hip replacement (TKR, THR) surgery (N = 5,510). Renal function, age, gender, and body weight impacted apixaban exposure. Bleeding risk increased as a function of exposure. Predicted bleeding frequencies for TKR and THR populations at risk for high apixaban exposure (female, age > 75 years, calculated creatinine clearance (cCrCL) < 30 ml/min, body weight < 50 kg) (6.85 and 10.3%, respectively) were comparable to the reference population (male/female, age 65-75 years, cCrCL ≥ 80 ml/min, body weight 65-85 kg) (6.18 and 9.32%, respectively). A 100% increase in apixaban exposure is expected to raise bleeding frequencies to 7.25% (TKR) and 10.9% (THR), whereas a 200% increase would raise them to 8.49 and 12.7%. Coexistence of combined patient risk factors or doubling of exposure is not likely to result in a substantial, clinically relevant increase in bleeding risk with 2.5 mg b.i.d. apixaban.
No takes yet. Share an insight, caveat, or question.
Leil et al. (2014) studied Total knee or hip replacement (TKR, THR) surgery (n=5,510). Apixaban vs. Reference population (age 65-75 years, cCrCL ≥ 80 ml/min, body weight 65-85 kg) was evaluated on Predicted bleeding frequencies (TKR population). Predicted bleeding frequencies for high-risk TKR and THR populations receiving apixaban twice daily were 6.85% and 10.3%, comparable to 6.18% and 9.32% in the reference population.
Synapse has enriched 10 related papers. Consider them for comparative context: